379 related articles for article (PubMed ID: 10383157)
1. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
Soga S; Neckers LM; Schulte TW; Shiotsu Y; Akasaka K; Narumi H; Agatsuma T; Ikuina Y; Murakata C; Tamaoki T; Akinaga S
Cancer Res; 1999 Jun; 59(12):2931-8. PubMed ID: 10383157
[TBL] [Abstract][Full Text] [Related]
2. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
[TBL] [Abstract][Full Text] [Related]
3. Stereospecific antitumor activity of radicicol oxime derivatives.
Soga S; Sharma SV; Shiotsu Y; Shimizu M; Tahara H; Yamaguchi K; Ikuina Y; Murakata C; Tamaoki T; Kurebayashi J; Schulte TW; Neckers LM; Akinaga S
Cancer Chemother Pharmacol; 2001 Dec; 48(6):435-45. PubMed ID: 11800023
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin.
Roe SM; Prodromou C; O'Brien R; Ladbury JE; Piper PW; Pearl LH
J Med Chem; 1999 Jan; 42(2):260-6. PubMed ID: 9925731
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.
Schulte TW; Akinaga S; Soga S; Sullivan W; Stensgard B; Toft D; Neckers LM
Cell Stress Chaperones; 1998 Jun; 3(2):100-8. PubMed ID: 9672245
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol.
Ikuina Y; Amishiro N; Miyata M; Narumi H; Ogawa H; Akiyama T; Shiotsu Y; Akinaga S; Murakata C
J Med Chem; 2003 Jun; 46(12):2534-41. PubMed ID: 12773056
[TBL] [Abstract][Full Text] [Related]
7. Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones.
Schulte TW; Akinaga S; Murakata T; Agatsuma T; Sugimoto S; Nakano H; Lee YS; Simen BB; Argon Y; Felts S; Toft DO; Neckers LM; Sharma SV
Mol Endocrinol; 1999 Sep; 13(9):1435-48. PubMed ID: 10478836
[TBL] [Abstract][Full Text] [Related]
8. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol.
Sharma SV; Agatsuma T; Nakano H
Oncogene; 1998 May; 16(20):2639-45. PubMed ID: 9632140
[TBL] [Abstract][Full Text] [Related]
9. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.
Bagatell R; Paine-Murrieta GD; Taylor CW; Pulcini EJ; Akinaga S; Benjamin IJ; Whitesell L
Clin Cancer Res; 2000 Aug; 6(8):3312-8. PubMed ID: 10955818
[TBL] [Abstract][Full Text] [Related]
10. Development of radicicol analogues.
Soga S; Shiotsu Y; Akinaga S; Sharma SV
Curr Cancer Drug Targets; 2003 Oct; 3(5):359-69. PubMed ID: 14529387
[TBL] [Abstract][Full Text] [Related]
11. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.
Marcu MG; Schulte TW; Neckers L
J Natl Cancer Inst; 2000 Feb; 92(3):242-8. PubMed ID: 10655441
[TBL] [Abstract][Full Text] [Related]
12. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
Bagatell R; Khan O; Paine-Murrieta G; Taylor CW; Akinaga S; Whitesell L
Clin Cancer Res; 2001 Jul; 7(7):2076-84. PubMed ID: 11448926
[TBL] [Abstract][Full Text] [Related]
13. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi M; Liu F; Tavorath R; Rosen N
Cancer Res; 2000 Jul; 60(14):3940-6. PubMed ID: 10919672
[TBL] [Abstract][Full Text] [Related]
15. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol.
Gadelle D; Bocs C; Graille M; Forterre P
Nucleic Acids Res; 2005; 33(7):2310-7. PubMed ID: 15849317
[TBL] [Abstract][Full Text] [Related]
17. Radanamycin, a macrocyclic chimera of radicicol and geldanamycin.
Wang M; Shen G; Blagg BS
Bioorg Med Chem Lett; 2006 May; 16(9):2459-62. PubMed ID: 16464590
[TBL] [Abstract][Full Text] [Related]
18. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
[TBL] [Abstract][Full Text] [Related]
19. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase.
Stancato LF; Silverstein AM; Owens-Grillo JK; Chow YH; Jove R; Pratt WB
J Biol Chem; 1997 Feb; 272(7):4013-20. PubMed ID: 9020108
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide.
Clevenger RC; Blagg BS
Org Lett; 2004 Nov; 6(24):4459-62. PubMed ID: 15548050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
